ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 0059 • ACR Convergence 2024

    Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance

    Susanna R. Bidgood1, Sophie Hopkin1, Kathryn R. Malpas1, David M. Kallenberg1, Jacqueline O’Neill1, Geofrey Odede1, Bernard Lauwerys2, Baran Ufuktepe3 and David Humphreys1, 1UCB Biopharma UK, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Istanbul, Turkey

    Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
  • Abstract Number: 0596 • ACR Convergence 2024

    Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation

    Marina Sánchez-Lucas1, Camille Bourgeois1, Juan Molina-Collada2, Teresa Gonzalez-Hernandez1, Juan Carlos Nieto Gonzalez1, Amparo Lopez-Esteban1, Ofelia Baniandres1, Esther Chamorro de Vega1 and Isabel Castrejon3, 1Hospital Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Hospital General Universitario Gregorio Marañon, Madrid, Spain

    Background/Purpose: Psoriatic arthritis (PsA) has a heterogenous clinical phenotype with manifestations in a number of different organs and systems. These include not only enthesitis, synovitis…
  • Abstract Number: 2278 • ACR Convergence 2024

    Similar Etanercept Adherence in Individuals with Rheumatic Disease Initiating Originator and Biosimilar: A Population-Based Study

    Olga Tsyruk1, Marina Birck2, Sasha Bernatsky2, Luck Lukusa3, Denis Choquette4, Gilles Boire5 and Walter Maksymowych6, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Rhumadata™, Montreal, QC, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment adherence is crucial to optimizing outcomes in rheumatic diseases. Suboptimal adherence is common with inflammatory and chronic diseases, often treated with biologics, including…
  • Abstract Number: 0131 • ACR Convergence 2024

    Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study

    Carol Hitchon1, Dawn Bowdish2, Gilles Boire3, Paul Fortin4, Louis Flamand5, Vinod Chandran6, Roya M Dayam7, Anne-Claude Gingras8, Catherine Card9, Ines Colmegna10, Maggie Larche2, Gil Kaplan11, Luck Lukusa12, Jennifer Lee12 and Sasha Bernatsky13, and SUCCEED investigative team, 1University of Manitoba, Winnipeg, MB, Canada, 2McMaster University, Hamilton, ON, Canada, 3Retired, Sherbrooke, QC, Canada, 4Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, 5Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, 6University of Toronto, Toronto, ON, Canada, 7Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, 8Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, 9National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, 10The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 11University of Calgary, Calgary, AB, Canada, 12The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 13Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
  • Abstract Number: 0603 • ACR Convergence 2024

    Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry

    Jakub Závada1, Jana Baranová2, Karel Pavelka1, Jiří Vencovský3, Pavel Horak4, Kateřina Kusalová2 and Ladislav Šenolt3, and collaborators of the ATTRA registry, 1Institute of Rheumatology and Charles University, Praha, Czech Republic, 2Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 43rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic

    Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
  • Abstract Number: 2279 • ACR Convergence 2024

    Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis Initiating Biologics or Targeted Synthetic DMARDs in Routine Care

    Isabel Castrejon1, Lucia Otero-Varela2, José María Álvaro-Gracia3, Jerusalem Calvo Gutierrez4, Cristina Campos-Fernández5, Alicia García Dorta6, Ana Perez7, DOLORES RUIZ MONTESINO8 and Fernando Sánchez-Alonso9, and on behalf of BIOBADASER, 1Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Hospital Gregorio Marañón, Madrid, Spain, 4HU Reina Sofia, Cordoba, Spain, 5Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, 6Rheumatologist, La Laguna, Spain, 7Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, 8Hospital Virgen Macarena, Sevilla, Spain, 9Sociedad Española de Reumatología, Madrid, Spain

    Background/Purpose: Glucocorticoids (GC) have a rapid effect on symptoms, but chronic exposure is associated to important adverse events. Although both EULAR and ACR guidelines (1,2),…
  • Abstract Number: 0146 • ACR Convergence 2024

    Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions

    Bashar Tanous1, SRIKAR SAMA2, Nidaa Rasheed3 and Candice Reyes4, 1UCSF Fresno, Fresno, 2University of California San Francisco Fresno, Fresno, CA, 3UCSF Fresno, Fresno, CA, 4VACCHCS, Fresno, CA

    Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
  • Abstract Number: 0806 • ACR Convergence 2024

    Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events

    Leah K. Flatman1, Sasha Bernatsky2, Isabelle Malhamé3, Yvan St-Pierre4, Olga Basso1, Anick Bérard5 and Evelyne Vinet3, 1McGill University, Montreal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4McGill University Health Center, Montreal, QC, Canada, 5Université de Montréal, Montreal, QC, Canada

    Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
  • Abstract Number: 2281 • ACR Convergence 2024

    Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab

    Monica Luque1, Kristina Zhelyazkova1, Laxmikant Vashishta2, Masna Rai3, Abid Sattar4, Richard Bucknall4, Steffen Leutz3 and FAUSTO BERTI1, 1Alvotech, Zürich, Switzerland, 2Alvotech, Bangalore, India, 3Alvotech, Jülich, Germany, 4Alvotech, London, United Kingdom

    Background/Purpose: Golimumab is a safe and effective treatment for RA. Biosimilars to the reference product (RP) may make treatment more accessible. We assessed comparable efficacy…
  • Abstract Number: 0172 • ACR Convergence 2024

    Effectiveness of mRNA COVID-19 Vaccines in Patients with Rheumatologic Conditions on Immunosuppressive Therapies

    Brandon Levian1, Charlotte Botz2, Jason Chwa2, Sophie Grove2, Vignesh Ravi2, Branden Ireifej3, daniel arkfeld4, Diana Hanna2, Jenny Hu2 and Binh Ngo2, 1Keck School of Medicine, Beverly Hills, CA, 2Keck School of Medicine, Los Angeles, 3LAGMC/Keck School of Medicine, Los Angeles, CA, 4Keck Medical Center of USC, RANCHO PALOS VERDES, CA

    Background/Purpose: Despite extensive data supporting the effectiveness of mRNA vaccines against SARS-CoV-2 in immunocompetent individuals, their efficacy in immunosuppressed patients remains uncertain. Consequently, this study…
  • Abstract Number: 0857 • ACR Convergence 2024

    Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study

    Yurilu Gonzalez Moret1, Diego Lema2 and Fabian Rodriguez Quinonez3, 1Jefferson Einstein Hospital, Philadelphia, PA, 2Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, 3Einstein Medical Center Philadelphia, Philadelphia, PA

    Background/Purpose: Immunosuppressive therapy, including Tumor necrosis factor inhibitors (TNFi), is commonly used in the treatment of various inflammatory conditions, including extracardiac sarcoidosis. However, the use…
  • Abstract Number: 2282 • ACR Convergence 2024

    Defining a Personalized Treatment Approach to Rheumatoid Arthritis: Using Genetic Markers of TNFi Response

    M. Elaine Husni, Judy Zhang, Jean Lin, Yuxuan Jin and Unnikrishnan Chandrasekharan, Cleveland Clinic, Cleveland, OH

    Background/Purpose: The development of a personalized medicine approach to identify responders and non-responders to tumor necrosis factor alpha (TNFα) inhibiting agents for rheumatoid arthritis (RA)…
  • Abstract Number: 0202 • ACR Convergence 2024

    Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

    Maria Suarez-Almazor1, Juan Ruiz2, Xiudong Lei1, Hui Zhao1, Suja Rajan3, Heather Lin1 and Sharon Giordano1, 1MD Anderson Cancer Center, Houston, TX, 2MD Anderson, Houston, TX, 3The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
  • Abstract Number: 0995 • ACR Convergence 2024

    What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?

    Ines Moninot1, ROLAND CHAPURLAT2, Elodie FEURER1, Pierre-Jean Cottinet3, Minh-Quyen Le3 and Aurélie Fontana1, 1Hospices Civils Lyon, Lyon, France, 2INSERM 1033, LYON, France, 3INSA Lyon, Lyon, France

    Background/Purpose: In developed countries, the impact of healthcare systems on the environment is sizeable (roughly 8% of the carbon footprint). So, it is essential to…
  • Abstract Number: 2323 • ACR Convergence 2024

    The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis

    Keith Colaco1, laura bumbulis2, Vinod Chandran1, Richard Cook3, Dafna Gladman4 and Lihi Eder5, 1University of Toronto, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3University of Waterloo, Waterloo, Canada, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology